Leon Chen - 17 Jun 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 17 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2022, 08:00:12 UTC
Prior SEC filing: 14 Jun 2021
Next SEC filing: 17 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrea Paul, as Attorney-in-Fact

Key filing fact

Leon Chen filed Form 4 for LogicBio Therapeutics, Inc. on 21 Jun 2022.

Key facts

This page summarizes Leon Chen's Form 4 filing for LogicBio Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2022, 08:00.

Change

Previous filing in this sequence was filed on 14 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LOGC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 17 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $0.3800
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy.

Footnote F2

The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.